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Abstract
A recent editorial in this journal provides a summary of key economic, social, and public health considerations of 
the forthcoming legislation to legalize, regulate, and restrict access to marijuana in Canada. As our government 
plans to implement an evidence-based public health framework for marijuana legalization, we reflect and expand 
on recent discussions of the public health implications of marijuana legalization, and offer additional points of 
consideration. We select two commonly cited public concerns of marijuana legalization – adolescent usage and 
impaired driving – and discuss how the underdeveloped and equivocal body of scientific literature surrounding 
these issues limits the ability to predict the effects of legalization.  Finally, we discuss the potential for some 
potential public health benefits of marijuana legalization – specifically the potential for marijuana to be used as a 
substitute to opioids and other risky substance use – that have to date not received adequate attention.  
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In light of the Canadian government’s plan to legalize, regulate, and restrict access to marijuana by Spring 2017, Dr. Hajizadeh’s editorial in this journal (“Legalizing and 
regulating marijuana in Canada: review of potential economic, 
social, and health impacts”)1 outlines a range of important 
points of consideration surrounding the potential economic, 
social, and public health impacts of marijuana legalization 
on a national level. Understandably, public health and safety 
are top concerns associated with the impending policy 
reform among the Canadian public. However, following a 
decade of Conservative government messaging that relied on 
exaggerated claims about the drug’s adverse health effects to 
reinforce its illegal status, discussions of the potential public 
health impacts of marijuana too often focus narrowly on a 
small set of findings that do not accurately reflect the state of 
the literature. As the newly elected Liberal government has 
expressed its intent to design an evidence-based framework 
that prioritizes public health, our aim is to review and expand 
upon points made in Dr. Hajizadeh’s editorial. 
Sadly, at present, the ability to make informed projections 
about the health impacts of marijuana legalization has long 
been complicated by a range of factors, including incomplete 
scientific experimentation and observation resulting from the 
drug’s longstanding illegal status, and a complete lack of other 
nationwide legalization experiences. For example, though the 
effect of marijuana on youth is rarely overlooked in discussions 
of the potential public health impacts of legalization, whether 
legalization will actually pose a problem to Canada’s youth 
remains unknown. While there is some evidence linking 
marijuana use in adolescence to cognitive and mental health 
problems, including exacerbating schizophrenia in affected 
individuals,2-4 it is important to stress that the state of the 
literature in this area remains contested, as emerging research 
continues to challenge conclusions made from previous 
well-known studies that have concluded negative impacts of 
marijuana on the brain. For instance, we are now learning 
that previously established links between marijuana use and 
schizophrenia may simply reflect increased marijuana use 
among individuals with a pre-disposition to schizophrenia5; 
links between marijuana use and impaired neurodevelopment 
may reflect structural brain differences that preceded 
marijuana initiation6; and links between marijuana use and 
lower intelligence may reflect lower socio-economic status 
among marijuana users,7 cigarette and alcohol use,8 and/or 
differences in genetic make-up and environmental exposures 
throughout childhood and adolescence.9 However, while 
studies showing little-to-no impact of cannabis on adolescent 
brain development and functioning receive virtually no 
attention from mainstream media or government-funded 
research organizations (eg, the Canadian Centre for Substance 
Abuse),10 studies suggesting a negative impact are broadly 
cited with little critical evaluation. 
Further, findings from studies of frequent marijuana use 
among youth tends to command the public discourse 
surrounding this topic, yet much less is known about the 
effect of moderate marijuana use among youth, which is 
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an essential component to our understanding of the effect 
of marijuana on young people. Currently, roughly half of 
Canada’s youth report that marijuana is easily accessible,11 
reflecting the highest rate of adolescent marijuana use of any 
developed nation.12 Considering the already high level of 
availability under the current system, many health and policy 
experts have long speculated that legalization is a favourable 
alternative to the current approach for preventing use among 
youth.13,14 This consensus is what largely justified the Liberal 
Government’s campaign promise to enact the legislation.15 In 
fact, based on the US medical marijuana experience, there is 
growing evidence to suggest that liberalization of marijuana 
policy does not promote increased usage among youth.16,17 
Adolescent marijuana use, mental health, and cognitive 
development are often cited as concerns of legalization, but 
these points also warrant serious consideration of potential 
positive impacts of legalization – consideration that is most 
often ignored in media discourse. 
Given the known impact of marijuana consumption on 
reduced attention span, motor skills, and slowed reaction 
time,18 motor vehicle injuries and fatalities are also a top 
public health concern of marijuana legalization. While several 
studies have examined the association between marijuana 
use and motor vehicle collisions, there is a high level of 
heterogeneity with regard to study design, study quality, and 
findings.19 A recent meta-analysis of the data estimates the 
risk to be significant yet low-to-moderate, and notes that 
the association is further reduced (yet still significant) after 
excluding studies that did not control for concurrent alcohol 
impairment.19 Determining whether marijuana legalization 
promotes increased motor vehicle collisions by way of 
increased prevalence of marijuana-impaired driving will 
undoubtedly be met with a host of challenges. 
Dr. Hajizadeh cautions that Canada may see an increase in 
marijuana-related traffic deaths after legalization, similar to the 
apparent experience in Colorado. It is important to note that 
attributing any increase in marijuana-related traffic fatalities 
in Colorado to marijuana legalization itself is challenging if 
not impossible. Unlike alcohol, there is no consensus on a 
standard of “impairment” for tetrahydrocannabinol (THC) – 
the primary psychoactive compound in marijuana – and THC 
metabolites can be detected in the blood or urine several days 
after consuming marijuana.20 Thus an increase in the presence 
of THC among drivers who suffered fatalities in Colorado 
may have simply reflected an increase in marijuana use 
among adults who drive, rather than an increase in marijuana-
impaired drivers.21 This is particularly plausible considering 
that the overall rate of fatal motor vehicle accidents in 
Colorado had been declining ahead of legalization21 and has 
continued to decline post legalization,22 despite an increase in 
the proportion of fatally injured drivers who test positive for 
THC. Finally, the possibility that legalization may promote 
increased marijuana testing among drivers needs to also be 
considered in these discussions. Drugged driving may prove to 
be a serious and legitimate concern of marijuana legalization; 
however, the current methods of determining marijuana 
impairment provide a clear impediment to evaluating the 
effect of legalization on motor vehicle accidents and fatalities. 
Overcoming this logistical challenge, which has yet to be 
publicly resolved by the Canadian government, will be critical 
to successful public health evaluation in this important area. 
Finally, Dr. Hajizadeh discusses a range of potential perceived 
adverse impacts of marijuana legalization, but we want 
to point out that there may in fact be a range of potential 
positive outcomes that could be of interest in preparation 
for the legislation and its eventual evaluation. Although Dr. 
Hajizadeh acknowledges marijuana’s therapeutic benefits 
for certain health conditions including neuropathic pain, 
inflammatory bowel disease, and managing symptoms of 
chemotherapy and treatment-resistant epilepsy, these issues 
may be more relevant to Canada’s medical marijuana laws 
and physician prescribing guidelines rather than discussions 
of full-scale legalization. While marijuana is associated with 
certain adverse effects discussed both in Dr. Hajizadeh’s 
editorial and here, there is also a great deal of consensus within 
the scientific community that cannabis is comparatively safer 
than a host of other commonly abused substances including 
alcohol, methamphetamine, cocaine, and illicit opioids.23 A 
recent study using data from all 50 US states found a 25% 
reduction in opioid-related overdose deaths in states that 
enacted medical marijuana laws during the 10-year study 
period, relative to those that did not.24 While it is unclear if 
increased substitution of opioids with marijuana is driving 
this finding, research among users of medical marijuana 
from various regions across North America demonstrates 
that marijuana is often used as a substitute for other risky 
substance use.25-27 Canada’s soaring opioid dependence and 
overdose rates reflect a national public health crisis that 
requires a national and multi-faceted approach. Whether 
marijuana legalization will offer a sort of “harm reduction” 
component to Canada’s response to the opioid crisis in not 
known, but it should not be overlooked. 
Canada is entering uncharted territory, as marijuana 
legalization of this magnitude is virtually void of scientific 
exploration. Furthermore, the body of research on the 
effects of marijuana alone remains underdeveloped, in large 
part due to its longstanding status as an illegal substance. 
Undoubtedly, Canada’s marijuana legalization will set a 
precedent for other governments looking to similarly reform 
marijuana legislation. We must ensure the policy is based on 
the science that has been presented fairly within the context 
of all evidence. Collectively, the single most important move 
that public health researchers and policy-makers can make 
is to put forward a long-term, adaptable research agenda 
that addresses a wide range of potential direct and indirect 
public health risks and benefits. A failure to do so will simply 
perpetuate the sad state of cannabis research internationally 
and result in policy that is not rooted in the best available 
evidence. 
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